Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination

Clin Case Rep. 2021 Aug 16;9(8):e04517. doi: 10.1002/ccr3.4517. eCollection 2021 Aug.


Rituximab and COVID-19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the timing of rituximab infusion and vaccination are urgently needed.

Keywords: COVID‐19 vaccine; lympholysis; pancytopenia; rituximab.

Publication types

  • Case Reports